In our AOM/DSS‐induced model, the group treated with anti‐PD1 antibody showed a slight decrease in tumor frequency and size without statistical significance, similar to the results of a previous study.[35] However, surprisingly, the frequency and size of tumors was significantly reduced in the groups treated with anti‐CXCL12 antibody, regardless of anti‐PD1 antibody treatment (Figure 7C,D). The gene discussed is CXCL12; the disease is neoplasm.